This FOA invites applications that will systematically and comprehensively characterize alpha-synuclein and amyloid-beta subspecies present in human Lewy Body Dementia (LBD) post-mortem brain tissue, identify toxic subspecies and potential mechanisms of toxicity, and characterize any interactions between
the proteins that may contribute to increased toxicity and/or explain selective vulnerabilities of cells/circuits.
Applications are required to include at least 3 hypothesis-driven projects that address these goals, an administrative core, and other cores as appropriate.
Applicants will be expected to focus on the use of human tissues.
All applications will be expected to include plans for developing a publicly-available library of fully characterized alpha-synuclein and amyloid-beta subspecies found in LBD.